Stella Hartono, MD
Allergy/Immunology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 2
Offices
2 locations · Stanford Health Care · Baz Allergy Asthma and Sinus Center Inc
Looking this up.
Hospitals listed: Community Regional Medical Center. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Hartono’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Community Regional Medical CenterFresno, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 1 of 5 starsWorse than the national rate — Death rate among surgical inpatients with serious treatable complications: 211.21 (174.88 to 247.54) · 239 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.705, Oct 2024 – Sep 2025
See every measure and the patient survey for Community Regional Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 3 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 211.21 (174.88 to 247.54) · 239 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.705 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.13 (0.29 to 1.96) · 2,304 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.09 (0.87 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 116 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.6 · 445 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.2 · 399 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 582 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 3,744 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.5) · 11,052 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,566 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.33 (1.64 to 5.01) · 3,139 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.08 (0 to 2.3) · 1,423 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.7 (0.52 to 2.88) · 3,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.85 (8.11 to 15.6) · 1,481 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.4 (3.81 to 8.98) · 1,404 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.35 (0.95 to 3.76) · 760 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.64 (0.16 to 1.11) · 10,254 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.817 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.031 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.837 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.81 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.853 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 258 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 689 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 37.4 · 202 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 35.2 · 543 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.2 · 434 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.3 · 552 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.6 to 7.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.3 to 15.4) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.4 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.6 · 248 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.9 (9.5 to 14.9) · 2,590 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 310 cases | No different | Jan 2024 – Dec 2024 |
What patients said (421 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$5,444
Medicare paid this office $5,444 for 42 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 31 | $2,287 | $74 |
| Test to measure expiratory airflow and volume | 21 | $478 | $23 |
| Test to measure the level of nitric oxide gas | 22 | $355 | $16 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 12 | $156 | $13 |
Who their Medicare patients are
42 Original Medicare patients in 2024. Average age 73 · Women 57% · Health risk score 0.96. At or below the middle of the specialty; the typical allergy/ immunology clinician is at 1.
Conditions among them: High blood pressure 75% · Coronary heart disease 38% · Diabetes 29% · Depression 29% · COPD 26%.
The office billed $10,810, Medicare allowed $6,833 and paid $5,444; for 357 services of 9 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Money from drug and device companies
$3,216 in 2025
| 2025 | 17 | 122 | None | $3,216 |
| 2024 | 5 | 7 | None | $502 |
| 2022 | 1 | 1 | None | $1,000 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Tezspire | $796 | 17 payments
|
| BioCryst US Sales Co. | Orladeyo | $640 | 23 payments
|
| Incyte | Opzelura | $497 | 16 payments
|
| Regeneron Healthcare Solutions | Dupixent | $268 | 13 payments
|
| GlaxoSmithKline | Nucala | $256 | 18 payments
|
| CSL Behring | Andembry | $249 | 10 payments
|
See all 115 published payments
| CSL Behring | Meals · 2025-12-20 | Andembry | $18 |
| Regeneron Healthcare Solutions | Meals · 2025-12-17 | Dupixent | $7 |
| BioCryst US Sales Co. | Meals · 2025-12-17 | Orladeyo | $29 |
| CSL Behring | Meals · 2025-12-16 | Andembry | $8 |
| GlaxoSmithKline | Meals · 2025-12-13 | Nucala | $16 |
| Ionis Pharmaceuticals | Meals · 2025-12-09 | Dawnzera | $38 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-04 | Breztri | $28 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-03 | Fasenra | $132 |
| ARS Pharmaceuticals Operations | Meals · 2025-12-03 | Neffy | $30 |
| BioCryst US Sales Co. | Meals · 2025-11-27 | Orladeyo | $13 |
| CSL Behring | Meals · 2025-11-26 | Andembry | $11 |
| BioCryst US Sales Co. | Meals · 2025-11-24 | Orladeyo | $36 |
| GlaxoSmithKline | Meals · 2025-11-21 | Nucala | $7 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-20 | Tezspire | $119 |
| BioCryst US Sales Co. | Meals · 2025-11-20 | Orladeyo | $39 |
| Paratek Pharmaceuticals | Meals · 2025-11-13 | Xhance | $23 |
| GlaxoSmithKline | Meals · 2025-11-13 | Trelegy Ellipta | $8 |
| BioCryst US Sales Co. | Meals · 2025-11-13 | Orladeyo | $37 |
| Regeneron Healthcare Solutions | Meals · 2025-11-08 | Dupixent | $61 |
| Incyte | Meals · 2025-11-01 | Opzelura | $12 |
| GlaxoSmithKline | Meals · 2025-10-31 | Nucala | $30 |
| CSL Behring | Meals · 2025-10-31 | Andembry | $8 |
| BioCryst US Sales Co. | Meals · 2025-10-30 | Orladeyo | $2 |
| GlaxoSmithKline | Meals · 2025-10-29 | Trelegy Ellipta | $24 |
| BioCryst US Sales Co. | Meals · 2025-10-29 | Orladeyo | $15 |
| Novartis Pharmaceuticals | Meals · 2025-10-28 | Rhapsido | $16 |
| BioCryst US Sales Co. | Meals · 2025-10-23 | Orladeyo | $114 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-10 | Fasenra | $21 |
| CSL Behring | Meals · 2025-10-10 | Andembry | $9 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-08 | Tezspire | $92 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-08 | Breztri | $26 |
| Regeneron Healthcare Solutions | Meals · 2025-10-03 | Dupixent | $26 |
| Regeneron Healthcare Solutions | Meals · 2025-10-03 | Dupixent | $38 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-01 | Tezspire | $27 |
| BioCryst US Sales Co. | Meals · 2025-09-29 | Orladeyo | $32 |
| Incyte | Meals · 2025-09-25 | Opzelura | $123 |
| GlaxoSmithKline | Meals · 2025-09-24 | Trelegy Ellipta | $12 |
| CSL Behring | Meals · 2025-09-24 | Andembry | $32 |
| Ionis Pharmaceuticals | Meals · 2025-09-24 | Dawnzera | $29 |
| GlaxoSmithKline | Meals · 2025-09-19 | Nucala | $28 |
| Regeneron Healthcare Solutions | Meals · 2025-09-18 | Dupixent | $8 |
| Incyte | Meals · 2025-09-12 | Opzelura | $11 |
| GlaxoSmithKline | Meals · 2025-09-11 | Trelegy Ellipta | $7 |
| BioCryst US Sales Co. | Meals · 2025-09-11 | Orladeyo | $33 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-06 | Fasenra | $6 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-05 | Fasenra | $17 |
| Pharming Healthcare | Meals · 2025-09-04 | Ruconest | $24 |
| Regeneron Healthcare Solutions | Meals · 2025-09-04 | Dupixent | $23 |
| Incyte | Meals · 2025-09-04 | Opzelura | $12 |
| Amgen | Meals · 2025-09-04 | Tezspire | $16 |
| Incyte | Meals · 2025-08-27 | Opzelura | $2 |
| Incyte | Meals · 2025-08-27 | Opzelura | $8 |
| GlaxoSmithKline | Meals · 2025-08-26 | Trelegy Ellipta | $11 |
| BioCryst US Sales Co. | Meals · 2025-08-26 | Orladeyo | $20 |
| Incyte | Meals · 2025-08-26 | Opzelura | $123 |
| Incyte | Meals · 2025-08-25 | Opzelura | $8 |
| Galderma Laboratories L.P. | Meals · 2025-08-20 | Nemluvio | $20 |
| BioCryst US Sales Co. | Meals · 2025-08-19 | Orladeyo | $9 |
| BioCryst US Sales Co. | Meals · 2025-08-19 | Orladeyo | $3 |
| GlaxoSmithKline | Meals · 2025-08-08 | Nucala | $33 |
| GlaxoSmithKline | Meals · 2025-08-08 | Trelegy Ellipta | $1 |
| GlaxoSmithKline | Meals · 2025-08-08 | Trelegy Ellipta | $9 |
| GlaxoSmithKline | Meals · 2025-08-06 | Trelegy Ellipta | $9 |
| Amgen | Education · 2025-08-01 | None | $34 |
| Galderma Laboratories L.P. | Meals · 2025-07-29 | Nemluvio | $110 |
| Incyte | Meals · 2025-07-26 | Opzelura | $9 |
| Pfizer | Meals · 2025-07-25 | Prevnar 20 | $17 |
| Amgen | Meals · 2025-07-21 | Tezspire | $19 |
| ARS Pharmaceuticals Operations | Meals · 2025-07-17 | Neffy | $28 |
| CSL Behring | Meals · 2025-07-16 | Andembry | $125 |
| BioCryst US Sales Co. | Meals · 2025-07-11 | Orladeyo | $33 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-28 | Fasenra | $20 |
| Regeneron Healthcare Solutions | Meals · 2025-06-27 | Dupixent | $6 |
| CSL Behring | Meals · 2025-06-27 | Haegarda | $14 |
| Incyte | Meals · 2025-06-23 | Opzelura | $17 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-13 | Tezspire | $18 |
| BioCryst US Sales Co. | Meals · 2025-05-31 | Orladeyo | $14 |
| GlaxoSmithKline | Meals · 2025-05-30 | Nucala | $25 |
| Regeneron Healthcare Solutions | Meals · 2025-05-30 | Dupixent | $9 |
| BioCryst US Sales Co. | Meals · 2025-05-23 | Orladeyo | $32 |
| Incyte | Meals · 2025-05-23 | Opzelura | $12 |
| CSL Behring | Meals · 2025-05-22 | Haegarda | $12 |
| BioCryst US Sales Co. | Meals · 2025-05-17 | Orladeyo | $14 |
| BioCryst US Sales Co. | Meals · 2025-05-15 | Orladeyo | $25 |
| BioCryst US Sales Co. | Meals · 2025-05-13 | Orladeyo | $35 |
| Genzyme | Meals · 2025-05-07 | Dupixent | $24 |
| Regeneron Healthcare Solutions | Meals · 2025-05-03 | Dupixent | $28 |
| GlaxoSmithKline | Meals · 2025-05-02 | Trelegy Ellipta | $8 |
| Incyte | Meals · 2025-04-29 | Opzelura | $1 |
| Incyte | Meals · 2025-04-29 | Opzelura | $8 |
| Grifols USA | Meals · 2025-04-29 | Xembify | $21 |
| Genzyme | Meals · 2025-04-18 | Dupixent | $27 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-17 | Airsupra | $21 |
| GlaxoSmithKline | Meals · 2025-04-11 | Nucala | $10 |
| Regeneron Healthcare Solutions | Meals · 2025-04-11 | Dupixent | $8 |
| Incyte | Meals · 2025-04-07 | Opzelura | $128 |
| Incyte | Meals · 2025-04-04 | Opzelura | $15 |
| BioCryst US Sales Co. | Meals · 2025-04-03 | Orladeyo | $15 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-27 | Tezspire | $28 |
| BioCryst US Sales Co. | Meals · 2025-03-25 | Orladeyo | $24 |
| Cycle Pharmaceuticals | Meals · 2025-03-21 | Sajazir | $22 |
| BioCryst US Sales Co. | Meals · 2025-03-20 | Orladeyo | $37 |
| GlaxoSmithKline | Meals · 2025-03-14 | Nucala | $7 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-13 | Seroquel | $25 |
| GlaxoSmithKline | Meals · 2025-03-12 | Trelegy Ellipta | $12 |
| Regeneron Healthcare Solutions | Meals · 2025-03-07 | Dupixent | $29 |
| Regeneron Healthcare Solutions | Education · 2025-03-04 | Dupixent | $7 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-19 | Tezspire | $125 |
| Regeneron Healthcare Solutions | Meals · 2025-02-18 | Dupixent | $17 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-11 | Tezspire | $21 |
| BioCryst US Sales Co. | Meals · 2025-02-10 | Orladeyo | $28 |
| Incyte | Meals · 2025-02-07 | Opzelura | $8 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-10 | Fasenra | $71 |
| ARS Pharmaceuticals Operations | Meals · 2025-01-07 | Neffy | $14 |
| CSL Behring | Meals · 2025-01-03 | Haegarda | $11 |
See earlier years (2024, 2022)
2024: $502
| Incyte | Opzelura | $138 | 2 payments
|
| Blueprint Medicines | None | $131 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Tezspire | $120 | 1 payment
|
| GlaxoSmithKline | Arexvy | $62 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $51 | 2 payments
|
2022: $1,000
| Regeneron Pharmaceuticals | None | $1,000 | 1 payment
|
Professional record
- NPI
- 1588195457
- Trained
- Mayo Medical School, 2017
- Group
- Stanford Health Care · Baz Allergy Asthma and Sinus Center Inc
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207K00000X (207K00000X); Pediatrics (208000000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2017-03-23
- NPI last updated
- 2026-01-09
- NPI record certified
- 2026-01-09
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 7471 N Fresno St, Fresno, CA, 93720 · 725 Welch Rd, Palo Alto, CA, 94304